Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: Long-term autologous transplantation experience in follicular and mantle cell lymphoma.
We recently described a novel thiotepa plus etoposide high-dose therapy (HDT) conditioning regimen for aggressive histology non-Hodgkin's lymphoma (NHL) that had low regimen-related toxicity (RRT) and an efficacy rate comparable to other NHL HDT regimens. In this report, we describe the UW experience with the addition of total body irradiation (TBI) and pre-transplant involved-field radiation (IFRT) to the thiotepa + etoposide HDT regimen. Between 1992 and 1999, 28 patients with indolent or mantle cell lymphoma were treated on this protocol. With a median follow-up of 64 mo, the median event-free survival (EFS) was 24 months, and the median overall survival (OS) had not been reached. The median number of grade 3 - 4 non-hematologic toxicities was five. There were five deaths (18%) in the first three months after HDT due to RRT. In contrast, the thiotepa + etoposide conditioning regimen (without TBI or IFRT) given to 65 intermediate grade NHL patients resulted in only one treatment-related death and considerably fewer grade 3 - 4 toxicities. Given the relatively short EFS in this cohort of indolent NHL patients, we conclude that the combination of IFRT and TBI plus thiotepa and etoposide resulted in a HDT regimen with excessive toxicity and this protocol was closed at our institution.
Fenske
Timothy S
TS
Section of Hematology and Bone Marrow Transplantation, Department of Internal Medicine, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA.
Kahl
Brad S
BS
Eickhoff
Jens
J
Mitchell
Teri L
TL
Smith
Eileen P
EP
Atkinson
Elizabeth
E
McCoy
Alice Garry
AG
Eckstein
Linda
L
Flynn
Bridget
B
McMannes
Jan
J
Howard
Steven
S
Longo
Walter L
WL
D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D013852:Thiotepa / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D013997:Time Factors; D014182:Transplantation, Autologous
D005047:Etoposide; D013852:Thiotepa